<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659047</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-312-0120</org_study_id>
    <nct_id>NCT01659047</nct_id>
  </id_info>
  <brief_title>A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and
      duration of tumor control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, single-arm, controlled, clinical trial evaluating the
      efficacy and safety of the phosphatidylinositol 3-kinase delta (PI3K-delta) inhibitor GS-1101
      (CAL-101) as therapy for previously treated chronic lymphocytic leukemia.

      This clinical trial (Study GS-US-312-0120) is a single-arm in which compliant subjects from
      GS US-312-0119 -Arm B who experience progression of CLL while receiving single-agent
      ofatumumab therapy are potentially eligible to receive single-agent, open-label GS 1101
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 mon</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Well-Being</measure>
    <time_frame>18 months</time_frame>
    <description>Health-related quality-of-life questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-related Biomarkers</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of plasma concentrations at peak (Cmax) and trough (Cmin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Resource Utilization</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>GS-1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-1101 (oral; 150 mg BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-1101</intervention_name>
    <description>150 mg taken twice daily by mouth</description>
    <arm_group_label>GS-1101</arm_group_label>
    <other_name>CAL-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in Study GS-US-312-0119

          -  Occurrence of confirmed progression of CLL while receiving single-agent ofatumumab in
             Study GS US 312 0119.

          -  Permanent cessation of Study GS-US-312-0119 (single-agent ofatumumab) and no
             intervening or continuing therapy (including radiotherapy, chemotherapy,
             immunotherapy, or investigational therapy) for the treatment of CLL.

          -  The time from permanent cessation of single-agent ofatumumab on Study GS-US-312-0119
             and the initiation of GS 1101 on Study GS-US-312-0120 is no more than 12 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Langdon Miller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>CAL-101</keyword>
  <keyword>Ofatumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

